December 6, 2007
`
`OPKO's Bevasiranib Named One of Most
`Promising Drugs Recently Entering Phase
`III Trials
`
`MIAMI, Dec. 6 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK) today reported
`that the gene silencing agent bevasiranib, OPKO's lead compound for the treatment of wet
`age-related macular degeneration (wet AMD), was named one of the top five most promising
`drugs entering Phase III clinical trials during the third quarter of 2007. The designation was
`reported in the current issue of The Ones to Watch report issued by Thompson Scientific
`Inc. Thompson's industry experts stated that their selections this quarter are intended to
`"showcase the ongoing drive to find therapies for diseases that impact on ageing and
`sedentary populations." Data for the Thompson report was compiled and analyzed using
`Thomson Pharma(R), a comprehensive global pharmaceutical information solution that
`covers the entire drug discovery and development pipeline.
`
`"We are very pleased to receive this recognition from Thompson Scientific since we believe
`bevasiranib has the potential to represent a major advance in the treatment of this common
`condition that limits the independence and quality of life of millions of older people around
`the globe," said Phillip Frost, M.D., Chairman and CEO of Opko Health. "Current vision-
`preserving therapy requires patients with wet AMD to receive intravitreal injections every four
`weeks, so the potential ability of bevasiranib to achieve similar results while requiring less
`frequent injections would be an important benefit for these patients, who often have limited
`mobility. Bevasiranib also has demonstrated excellent safety in clinical trials to date, another
`important consideration in this patient population."
`
`Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the
`genes that produce vascular endothelial growth factor (VEGF), believed to be largely
`responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the
`Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase III clinical
`trials.
`
`The multi-national Phase III COBALT (Combining Bevasiranib And Lucentis Therapy) clinical
`trial of bevasiranib for the treatment of wet AMD is currently enrolling patients at multiple
`clinical sites. For more information about the COBALT trial, please visit
`www.opko.com/clinicaltrials
`
`About OPKO Health, Inc.
`
`Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the
`pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after
`successfully completing Phase II trials for wet age-related macular degeneration and diabetic
`macular edema. OPKO is developing a preclinical pipeline of novel agents for ophthalmic
`diseases, and it markets innovative diagnostic imaging systems that complement the
`company's therapeutic products. For more information visit the company's website at
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2131 Page 1
`
`

`

`www.opko.com.
`
`This press release contains "forward-looking statements," as that term is defined under the
`Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be
`identified by words such as "expects," "plans," "projects," "will," "may," "anticipates,"
`"believes," "should," "intends," "estimates," and other words of similar meaning, including
`statements regarding bevasiranib's potential ability to achieve similar results as current
`therapies while requiring less frequent injections, statement's about bevasiranib's safety
`profile, which might not be as important to patients as anticipated, statements about our
`product development efforts, and our ability to develop a preclinical pipeline of novel agents
`for ophthalmic diseases, as well as other non-historical statements about our expectations,
`beliefs or intentions regarding our business, technologies and products, financial condition,
`strategies or prospects. Many factors could cause our actual activities or results to differ
`materially from the activities and results anticipated in forward-looking statements. These
`factors include those factors described in our filings with the Securities and Exchange
`Commission, as well as risks inherent in funding, developing and obtaining regulatory
`approvals of new, commercially-viable and competitive products and treatments, including
`the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be
`successful, that the Phase III clinical trial itself may not be completed on a timely basis or at
`all, that any of our compounds under development, including bevasiranib, may fail, may not
`achieve the expected results or effectiveness and may not generate data that would support
`the approval or marketing of products for the indications being studied or for other
`indications. In addition, forward-looking statements may also be adversely affected by
`general market factors, competitive product development, product availability, federal and
`state regulations and legislation, the regulatory process for new products and indications,
`manufacturing issues that may arise, patent positions and litigation, among other factors.
`The forward-looking statements contained in this press release speak only as of the date the
`statements were made, and we do not undertake any obligation to update forward-looking
`statements. We intend that all forward-looking statements be subject to the safe-harbor
`provisions of the PSLRA.
` Contacts: Media:
` Corporate: GendeLLindheim BioCom Partners
` Steven D. Rubin Barbara Lindheim
` 305 575 6000 212 918-4650
`
`SOURCE OPKO Health, Inc.
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2131 Page 2
`
`